Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
0.464
-0.028 (-5.63%)
At close: Nov 4, 2024, 4:00 PM
0.465
+0.001 (0.22%)
Pre-market: Nov 5, 2024, 4:51 AM EST
Enveric Biosciences Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Nov '24 Nov 4, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 4 | 3 | 4 | 29 | 793 | - | |
Market Cap Growth | -30.69% | -30.19% | -85.19% | -96.32% | - | - | |
Enterprise Value | 1 | -1 | -16 | 8 | 795 | - | |
Last Close Price | 0.46 | 1.30 | 2.08 | 46.50 | 213.00 | - | |
PE Ratio | - | -0.16 | -0.16 | -0.45 | -3.57 | - | |
PB Ratio | 0.68 | 1.54 | 0.28 | 1.31 | 232.13 | - | |
P/FCF Ratio | -0.49 | -0.21 | -0.24 | -2.51 | -203.89 | - | |
P/OCF Ratio | -0.49 | -0.21 | -0.25 | -2.55 | -203.89 | - | |
EV/EBITDA Ratio | 0.15 | 0.08 | 0.82 | -0.31 | -144.65 | - | |
EV/EBIT Ratio | 0.15 | 0.08 | 0.80 | -0.31 | -141.53 | - | |
EV/FCF Ratio | 0.15 | 0.09 | 0.90 | -0.66 | -204.44 | - | |
Debt / Equity Ratio | - | - | 0.00 | 0.01 | - | -0.41 | |
Debt / FCF Ratio | - | - | 0.00 | -0.02 | - | -1.14 | |
Quick Ratio | 5.89 | 1.07 | 4.44 | 8.33 | 2.32 | 0.02 | |
Current Ratio | 8.55 | 1.53 | 4.61 | 8.51 | 3.35 | 0.06 | |
Return on Equity (ROE) | -206.10% | -197.47% | -97.57% | -380.82% | -855.92% | - | |
Return on Assets (ROA) | -80.50% | -86.20% | -53.92% | -102.60% | -166.96% | -1183.53% | |
Return on Capital (ROIC) | -124.00% | -116.97% | -65.49% | -122.09% | -299.51% | - | |
Earnings Yield | -255.98% | -573.01% | -427.30% | -167.81% | -0.87% | - | |
FCF Yield | -241.11% | -467.23% | -410.17% | -39.91% | -0.49% | - | |
Buyback Yield / Dilution | -98.81% | -49.31% | -206.13% | -310.48% | -8.82% | 6.45% | |
Total Shareholder Return | -98.81% | -49.31% | -206.13% | -310.48% | -8.82% | 6.45% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.